New Cancer Drug Shrinks Tumors in 62% of Lung Cancer Patients

A drug company just announced results that could change the game for two of the toughest cancers to treat.

Erasca reported Monday that its experimental pill, ERAS-0015, shrank tumors in 62% of patients with advanced non-small cell lung cancer and 40% of patients with advanced pancreatic cancer. These early results surpassed what the company expected to see.

The drug targets RAS, a protein that drives cancer growth in many tumor types. For decades, RAS was considered "undruggable," but recent scientific breakthroughs have opened new doors for patients who previously had few options.

The studies tested the pill in patients across the United States and China who had advanced disease. Erasca CEO Jonathan Lim told STAT he's particularly excited about the lung cancer data, calling it "more definitive" at this point, while the pancreatic results continue to develop.

Pancreatic cancer remains one of the deadliest cancers, with survival rates that have barely budged in decades. Non-small cell lung cancer, while more treatable than in the past, still claims tens of thousands of lives each year in the U.S. alone.

The company compared its results favorably to a similar drug from Revolution Medicines that recently doubled survival time in pancreatic cancer patients. Having multiple drugs targeting the same pathway could mean more treatment options tailored to individual patients.

The Ripple Effect

These results represent more than just numbers on a clinical trial readout. Behind every percentage point are real people and families who've been searching for hope in the face of devastating diagnoses.

The progress on RAS-targeting drugs shows how scientific persistence pays off. What seemed impossible just years ago is now becoming reality in clinic after clinic.

While the data remains preliminary and needs confirmation in larger studies, the strong response rates and good tolerability give researchers confidence to move forward. Erasca plans to continue developing both the lung and pancreatic cancer programs.

For the thousands diagnosed with these cancers each year, every new treatment option brings the possibility of more time, better quality of life, and renewed hope for their families.

Scientific breakthroughs like this remind us that the future of cancer treatment keeps getting brighter.